Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.89 |
| ▸ | MAPT | P10636 | 4/20 | 0.89 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.89 |
| ▸ | TP53 | P04637 | 3/20 | 0.89 |
| ▸ | TSHR | P16473 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | THPO | P40225 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.89 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | GMNN | O75496 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886920 | 1.00 | MEN1 (0.89) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL28699982 | 0.98 | MEN1 (0.86) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL9574613 | 0.98 | MEN1 (0.86) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL235082 | 0.95 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL8977796 | 0.95 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL9065214 | 0.94 | MEN1 (0.84) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL25373354 | 0.94 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL17164609 | 0.94 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL288242 | 0.94 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL188470 | 0.94 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| CN-119534850-A | Marker group capable of reflecting prolongation of post-PCI proinflammatory period of ACS patient and application thereof | 天津中医药大学 | 2025-02-28 | — | — | CN | claimed |
| CN-115395108-B | Preparation method and application of aqueous electrolyte containing quaternary ammonium salt type amphoteric ion additive | 中南大学 | 2024-09-10 | — | — | CN | claimed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | UNIVERSITY OF SOUTH CAROLINA | 2024-03-21 | — | — | US | claimed |
| CN-117686624-A | Method for simultaneously measuring 28 amino acids, carnitine, lysolecithin and ceramide in serum | 首都医科大学附属北京朝阳医院 | 2024-03-12 | — | — | CN | claimed |
| CN-117174923-B | Graphite felt for enhancing solid-liquid interface interaction and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117174923-A | Graphite felt for enhancing solid-liquid interface interaction and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2023-12-05 | — | — | CN | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| CN-114026427-B | Marker for diagnosing kidney disease and diagnostic method | 深圳市中医院 | 2023-11-17 | — | — | CN | claimed |
| WO-2000000183-A2 | ANTIOXIDANT, CYTOSTATIC AND SUSTAINED ENERGY COMPOSITION WHICH AMELIORATES THE METABOLIC UTILIZATION OF GLUCOSE COMPRISING ACETYL-L-CARNITINE AND A CATECHIN | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2000-01-06 | — | — | WO | claimed |
| WO-1999066914-A2 | NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION, COMPRISING ACETYL-L-CARNITINE AND HYPERICIN | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-12-29 | — | — | WO | claimed |
| WO-1999066913-A2 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, COMPRISING PROPIONYL-L-CARNITINE AND GENISTEIN | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-12-29 | — | — | WO | claimed |
| WO-1999053921-A1 | COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND NADH AND/OR NADPH | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-10-28 | — | — | WO | claimed |
| WO-1999052517-A2 | COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-21 | — | — | WO | claimed |
| US-RE36331-E | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-05 | — | — | US | claimed |
| EP-0722724-B1 | Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants | SIGMA TAU IND FARMACEUTI (IT) | 1999-03-24 | — | — | EP | claimed |
| WO-1999006039-A1 | COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND LONG-CHAIN ALKANOLS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-02-11 | — | — | WO | claimed |
| WO-1999001126-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-01-14 | — | — | WO | claimed |
| US-5496821-A | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | NDUFAB1, OAT, CPT2 | MEN1 3476/4885KMT2A 2356/4885MAPT 1246/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | MEN1 2449/4885KMT2A 1149/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.